Schellenberg Wittmer has provided legal counsel to Santhera Pharmaceuticals Holding in the sale of its Raxone®/idebenone business for all indications worldwide to Chiesi Farmaceutici. The deal marks a significant update to the existing license
Tags :Philipp Groz
Santhera Pharmaceuticals Holding has announced the grant of an exclusive North America license for the commercialization of vamorolone to Catalyst Pharmaceuticals for a total consideration of up to USD 231 million
Schellenberg Wittmer advised Santhera Pharmaceuticals regarding an exclusive license agreement for the Greater China Region with Sperogenix Therapeutics, a China-based company specialising in orphan diseases. Under this agreement, Sperogenix will in-license the drug candidate Vamorolone
Graphic Packaging Holding Company has reached a definitive agreement with CVC Capital Partners Fund to acquire AR Packaging Group for approximately $1.45 billion. The Advisors Schellenberg Wittmer is acting as legal counsel to Graphic packaging
The team at Schellenberg Wittmer advising on the carve-out transaction was led jointly by Christoph Vonlanthen and Oliver Triebold
